Total Payments
$9,555
2024 Payments
$1,594
Companies
63
Transactions
560
Medicare Patients
4,327
Medicare Billing
$563,058
Payment Breakdown by Category
Food & Beverage$7,620 (79.8%)
Other$1,098 (11.5%)
Education$836.51 (8.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,620 | 531 | 79.8% |
| Long term medical supply or device loan | $1,098 | 12 | 11.5% |
| Education | $836.51 | 17 | 8.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,723 | 53 | $0 (2024) |
| Genentech USA, Inc. | $717.11 | 54 | $0 (2021) |
| Janssen Biotech, Inc. | $606.40 | 35 | $0 (2024) |
| PFIZER INC. | $592.41 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $538.64 | 44 | $0 (2023) |
| Amgen Inc. | $486.76 | 27 | $0 (2021) |
| Incyte Corporation | $446.62 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $391.34 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $373.10 | 28 | $0 (2023) |
| Celgene Corporation | $333.75 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,594 | 36 | Novartis Pharmaceuticals Corporation ($1,145) |
| 2023 | $332.31 | 9 | Incyte Corporation ($99.00) |
| 2022 | $194.59 | 10 | Dendreon Pharmaceuticals LLC ($73.32) |
| 2021 | $346.32 | 12 | Janssen Biotech, Inc. ($111.09) |
| 2020 | $123.41 | 8 | Janssen Biotech, Inc. ($43.87) |
| 2019 | $2,201 | 149 | Genentech USA, Inc. ($224.09) |
| 2018 | $2,296 | 162 | Genentech USA, Inc. ($219.69) |
| 2017 | $2,466 | 174 | Novartis Pharmaceuticals Corporation ($329.43) |
All Payment Transactions
560 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $14.50 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| 10/23/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Diagnostic Imaging | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $29.33 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $11.30 | General |
| Category: Interventional Oncology | ||||||
| 08/28/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $9.92 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/07/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: HEMATOLOGY | ||||||
| 07/24/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Oncology | ||||||
| 07/23/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/10/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.06 | General |
| Category: Hematology | ||||||
| 06/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 838 | 1,662 | $389,610 | $117,510 |
| 2022 | 10 | 988 | 1,973 | $344,543 | $140,166 |
| 2021 | 9 | 976 | 2,160 | $371,548 | $157,146 |
| 2020 | 22 | 1,525 | 3,083 | $431,201 | $148,236 |
Total Patients
4,327
Total Services
8,878
Medicare Billing
$563,058
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 457 | 1,183 | $264,685 | $79,139 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 105 | 105 | $44,541 | $13,795 | 31.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 84 | $14,908 | $5,114 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 92 | 109 | $16,889 | $5,108 | 30.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 46 | $14,075 | $4,550 | 32.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 41 | $13,700 | $3,990 | 29.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $12,705 | $3,285 | 25.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 37 | 67 | $8,107 | $2,531 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 492 | 1,305 | $202,275 | $89,057 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 89 | 89 | $30,972 | $11,724 | 37.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 59 | 81 | $20,177 | $8,890 | 44.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 47 | $18,941 | $6,919 | 36.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 109 | 130 | $13,910 | $5,983 | 43.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 48 | 51 | $16,728 | $5,315 | 31.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 52 | 92 | $15,732 | $5,070 | 32.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 66 | 143 | $17,303 | $4,277 | 24.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 21 | $4,893 | $1,665 | 34.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $3,612 | $1,266 | 35.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 531 | 1,497 | $232,035 | $106,607 | 45.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 102 | 102 | $35,496 | $13,669 | 38.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 54 | 75 | $18,600 | $8,119 | 43.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 50 | 115 | $19,665 | $6,424 | 32.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 97 | 111 | $11,877 | $5,388 | 45.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 39 | 49 | $16,072 | $5,176 | 32.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 32 | 32 | $12,896 | $4,955 | 38.4% |
About Dr. John Cho, MD
Dr. John Cho, MD is a Medical Oncology healthcare provider based in New Bern, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659310332.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Cho, MD has received a total of $9,555 in payments from pharmaceutical and medical device companies, with $1,594 received in 2024. These payments were reported across 560 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($7,620).
As a Medicare-enrolled provider, Cho has provided services to 4,327 Medicare beneficiaries, totaling 8,878 services with total Medicare billing of $563,058. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New Bern, NC
- Active Since 06/06/2006
- Last Updated 01/20/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1659310332
Products in Payments
- KISQALI (Drug) $1,170
- OPDIVO (Biological) $393.52
- PROVENGE (Drug) $319.86
- IMBRUVICA (Drug) $296.12
- KEYTRUDA (Biological) $270.42
- XTANDI (Drug) $213.30
- TECENTRIQ (Biological) $182.99
- Avastin (Biological) $153.45
- Abraxane (Drug) $152.93
- LYNPARZA (Drug) $147.21
- AFINITOR (Drug) $145.56
- IBRANCE (Drug) $139.12
- Nplate (Biological) $134.37
- Imbruvica (Drug) $132.64
- Stivarga (Drug) $128.67
- Aranesp (Biological) $127.80
- Erleada (Drug) $122.64
- GILOTRIF (Drug) $115.40
- JADENU (Drug) $110.11
- Perjeta (Biological) $108.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.